Quietmind Foundation

  • Quietmind Foundation
    • Services
    • Clinical Trials >
      • Light Therapy Single Subject Study
      • Intranasal PBM for Long-COVID
  • Quietmind Associates
    • Home Neurofeedback >
      • Research - IRB Review
    • Phototherapeutics & Neurofeedback >
      • Neurofeedback
      • Photobiomodulation (Light Therapy)
    • Equipment
  • Contact
  • BLOG


​Leading Edge Commentary

Post-COVID 19 Dementia Increasing Worldwide

3/10/2022

0 Comments

 
COVID ups risks of dementia, cognitive impairment, and decline in older survivorsSadly and not surprisingly, the science media is reporting that the neurological impact of covid 19 is showing increased levels of cognitive decline worldwide. Older adults are having to cope with damage to their lungs and central nervous system. The study noted that the telephone survey measures used were limited in identifying more specific challenges and likely underestimate the size of the problem due to having excluded subjects with any family history of dementia. The global dementia care burden is likely to be greater as a result of the COVID-19 pandemic and so there is even greater need to rapid intervention now that can be easily, safely and cost effectively deployed. Researchers and clinicians at Quietmind Foundation, Neuronic Devices Ltd (Neuronic.online), Baylor Research Institute and the Biophotonic and Neuroimaging Lab•UTexas-Arlington are collaborating to show the effectiveness of self-administered, transcranial infrared light-based therapy to reduce dementia's cognitive and behavioral symptoms. 

The Neuradiant 1070 4Q technology that's being released this month by Neuronic Devices Ltd. 
(see Neuronic.online) is a resource that can address the debilitating impact of COVID 19 on the brain by increasing cortical perfusion and ATP production by stimulating cytochrome c oxidase and improving blood vessel flexibility. In addition, the new independent 4 -quadrant control of pulse frequency allows for renormalization of dysregulated brain network connectivity using the light pulsations to directly changes in EEG activity. 

https://arstechnica.com/science/2022/03/covid-ups-risks-of-dementia-cognitive-impairment-and-decline-in-older-survivors/
0 Comments

March 04th, 2022

3/4/2022

0 Comments

 

Mental disorders in early life are associated with a significantly increased risk of dementia in later years.
Results of a large, longitudinal, population-based study show that individuals hospitalized for a mental health disorder had a fourfold increased relative risk (RR) for developing dementia compared to those who were not hospitalized with a mental illness. This should come as no surprise to psychotherapists and those involved with treating individuals with trauma in their history. Researchers have already reported on the increased incidence of early onset dementia with any history of head trauma and other studies have clearly correlated the exhibiting of violent behavior with the degree of diagnosable brain trauma a person has sustained. 

We must become evermore cognizant of the need to have the differential diagnosis for the entire range of psychiatric and behavioral disorders across the lifespan include a neurotrauma/biophysical/toxicological trauma component. 

Quietmind has evolved it's evaluation protocol according to this tripartite framework, wherein we employ functional medicine to determine the contribution of mold and other neurotoxins, bacterial and viral infections, genetic predispositions and lifestyle factors. That data is combined with individual Quantitative EEG neurophysiological, systems-oriented psychological and  neuropsychiatric assessments.   


Article click here: www.medscape.com/

0 Comments

​Mental Illness Tied to Increased Dementia Risk

3/4/2022

0 Comments

 
Batya Swift Yasgur, MA, LSW March 02, 2022
www.medscape.com/

This article increases the clarity as to how severe emotional stress and dysregulation contribute to the development of neurodegenerative disorders like Alzheimer's, and Parkinson's disease. We have to come to see how mind and body work together to enhance or destroy our capacity for health and well being. Anyone who has been hospitalized for psychiatric illness is at a 4 fold greater risk of developing a neurodegenerative disorder than those who have not been hospitalized. 
Greater attention and effort needs to be placed toward prevention and reducing hospitalization for people experiencing emotional crises.
​


0 Comments

Long Covid Cognitive Decline Found in

2/25/2022

0 Comments

 
Picture

There is growing recognition and subsequent real concern about the number of young people who are now reporting diminished cognitive functioning after having been infected with COVID 19. These reports are from those with severe to asymptomatic experiences of acute infection and the chronic symptoms have surfaced sometimes months post recovery. Our view is that the global neuroinflammatory and thrombotic effects are key drivers for long COVID neurological symptoms and that 1070nm transcranial photobiomodulation (TPBM) can offer a method for symptom mitigation. 

Quietmind and Neuronic Devices Ltd. (neuronic.online) are collaborating with our colleagues at Durham Univ. and the Univ. of Texas-Arlington to study the variable impact of the Neuradiant 1070 4Q device ​on infectivity, virulence and post infection neuropsychological and neurophysiological symptoms. 

www.medrxiv.org/content/10.1101/2022.06.07.22276020v1.full
0 Comments

Novel Biomarker (Aβ42) found for Alzheimer's Disease

1/25/2022

0 Comments

 
This report involves the recognition of Aβ42, a protein that function as as a neurotoxin and now attributed to the development of Alzheimer's disease 

Key Takeaways
  • Measurement of the rate of cellular amyloid uptake and metabolic production of toxic amyloid species could be used as novel biomarkers for early and/or differential diagnosis of Alzheimer's disease (AD).
  • Estimated beta-amyloid (Aβ42) cellular uptake can be more than two times greater in AD patients compared to cognitively normal subjects. A less pronounced yet increased uptake rate was also observed in patients with late-onset mild cognitive impairment (MCI).
  • This increased uptake may prove to be a key mechanism defining age-related AD progression.
  • ​The increased cellular amyloid uptake in AD and LMCI may lead to quicker disease progression, but early-onset MCI may result from increased production of toxic amyloid metabolites.​
Of particular relevance is that the Aβ42 protein was shown to be significantly reduced in animal trials involving 1072nm photobiomodulation by researchers at Durham University. (Grillo, 2013) showed that this particular protein along with several others were reduce in the animals that showed improved cognitive and behavioral functioning after a trial of light stimulation. This is the same wavelength of light being used in the Neuradiant 1070 4Q transcranial photobiomodulation technology available now through Neuronic Devices Ltd. (neuronic.online) 


(Grillo SL, Duggett NA, Ennaceur A, Chazot PL (2013). Non-invasive infra-red therapy (1072nm) reduces β-amyloid protein levels in the brain of an Alzheimer’s disease mouse model, TASTPM. J Photochem Photobiology B Biology, 123:13–22.)

Full article here: www.medscape.com/viewarticle/

0 Comments

ECT: Is safe to treat mental disorders

11/24/2021

0 Comments

 

a large study just released shows that electroconvulsive therapy (ECT)

https://mail.google.com/mail/u/0/#inbox/FMfcgzGllCdXGfSqVnvHjFmcFJQcJBjv?
0 Comments

Bioenergetic Analysis and Neurotherapy

11/2/2021

0 Comments

 
I wanted to add a note here by way of background to understand how I think about neuromodulation and its relationship to psychotherapy and the healing process. I practiced as a psychotherapist for many years before becoming a psychologist in 1999. It then became clear by 2010 that the bulk of my clinical work would not fit within the scope of practice of Psychology. I found that psychoneurophysiology is a better term for what I was doing given the use of neurofeedback, photic and electromagnetic stimulation that then was combined with Bioenergetic Therapy (see link below). I offer this by way of explaining my theoretical and clinical perspective on treatment which leans heavily on  neo-Reichian, general systems and psychodynamic theory and now digital neurotherapeutics and photobiomodulation.

Much of my focus is on larger systemic (interpersonal, group-as-a-whole, socio-cultural) factors and how those dynamics influence activity at the individual (person system) level. I use the idea of character armoring as it was defined by Reich and Lowen to capture the expression of trauma as it manifests physically as specific patterns of chronic muscular tension. These patterns then influence the other structive elements, e.g., fascial and neurodevelopmental maturation. All the pieces are connected as the old song taught us. 

I recognized that the isomorphic pattern of contraction and expansion that defined character armor also manifested in the neurophysiological level as constrained dominant frequency activity that could be observed in the patterned behavior of the dominant EEG activity both in terms of absolute range of manifest frequency and variability within the range. Now its clear that we can use this way of understanding the flow of energy in the body to support healing using the noninvasive tools of photobiomodulation and functional medicine. The emotional/psychological aspects of healing can be best addressed using body-centered techniques that can help people unlock and express their full potential. It is very gratifying to me to see how all the pieces fit together and to then be able to help others learn as well. Some see these principles now as 'biohacks' and that doesn't really get at the heuristic quality but then heuristics aren't what they used to be along with pretty much everything else.

For a quick outline of Bioenergetics
​www.goodtherapy.org/learn-about-therapy/types/bioenergetic-analysis
0 Comments

Photobiomodulation, Depression, Anxiety and Cognition

10/27/2021

0 Comments

 
This is a review paper that explores the uses of light therapy in treating depression, anxiety and Cognitive challenges especially among the elderly where effective treatment options are limited and often creating more problems than they solve. PBM is described as possibly 'filing a gap in areas where more mainstream interventions do not help to directly alleviate the highly negative impact of various forms of persistent anxiety, which often accompanies depression, nor pathways inducing associated feelings of sadness, helplessness, loss of interest in self-care as well as pleasure in daily activities in a practical as well as possibly in an observable functional and neural context.'

I have said for many years when I worked as a body-centered psychotherapist that what is often diagnosed as depression is more often the resulting state of chronic anxiety. The application of PBM has been shown to help elevate mood and provide people with more physical and emotional energy. The paper's author Ray Marks, commented on this in saying, "For vulnerable older adults who cannot exercise readily and do not respond favorably to antidepressant medications, it appears that non-thermal non-invasive applications of visible or near infrared light transcranial neuro-stimulation may be able to stimulate or inhibit targeted biological cells and tissues that undermine emotional health via a reproducible photochemical mechanism."

It is encouraging to see faculty from within elite schools within educational research community coming beginning to view PBM's potential as a resource for remediation of the serious neuropsychiatric and neurodegenerative conditions in the elderly. I hope they will soon look down the telescope the other way and apply this insight to the children in our society who're needing relief from the overwhelming anxiety and resultant depression wrought by living in this era of endemic gun violence and pandemic-induced terror. The tools are available now to provide safe, reliable, low-cost, easily deployed help to our children and older adults. 



1pbm_depression_anxiety_and_cognition.pdf
File Size: 420 kb
File Type: pdf
Download File

0 Comments

Helmet that 'Zaps Away Dementia

10/19/2021

0 Comments

 
The Daily Mail today published a brief article describing a new research report that appeared yesterday in the research journal Photobiomodulation, Photomedicine and Laser Surgery. The report documents the effectiveness of brief intensive transcranial light stimulation using near infrared light at 1065-1080nm. The results with a cohort of normal subjects showed that the group receiving active treatment improved on measures of memory, motor functioning and processing speed. This supports the findings of the recently published report by Baylor Research Institute and Quietmind Foundation on the use of this same device with 100 subjects diagnosed with Alzheimer's and some also with Parkinson's disease. The results in both trials were very similar and quite encouraging. Further studies are needed to refine the treatment method for different clinical groups. The Cognitolite device is now available through Quietmind Foundation as well as the Neuradiant 1070 device now available through Neuronic Devices Ltd. (neuronic.online) that uses the 1070nm frequency and also allows for independent control of stimulation location, pulse frequency, duration and intensity. This unit is designed to provide both remediation, cognitive enhancement and protection against further injury.
​
pbm_-_normal_people.pdf
File Size: 178 kb
File Type: pdf
Download File

Picture
Picture
0 Comments

Microglia Control Cortical Perfusion

10/17/2021

0 Comments

 
New research from Univ. of Virginia Brain Immunology and Glia lab is showing how microglia influences cortical perfusion by controlling expansion and contraction of capillaries. This important finding supports previously reported findings on how transcranial photobiomodulation (PBM) could effect] cortical perfusion. In the study conducted at Quietmind Fdn., researchers used near infrared spectroscopy to measure the change in perfusion volume at the cortex surface from repeated, brief exposure to 1070nm pulsed PBM. Further, recent investigations have now shown how this type of therapeutic application of PBM can improve both cognitive, mood and motor functioning in people diagnosed with mild cognitive impairment and mild to moderate Alzheimer's disease. 

 Devices based on these findings are now available under clinical supervision through Quietmind Foundation. Inquiries should be directed to Marvin Berman PhD 610-940-0488 

Read the UVA article 
here.
0 Comments
<<Previous
Forward>>

    QMF News

    Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general. 

    Archives

    June 2025
    March 2025
    January 2025
    December 2024
    October 2024
    July 2024
    March 2024
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    August 2022
    July 2022
    June 2022
    April 2022
    March 2022
    February 2022
    January 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    June 2019
    May 2019
    April 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    March 2018
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    May 2017

    Categories

    All
    Alzheimer's
    Biofeedback
    Breathing Training
    Dementia
    Dementia Treatment
    Drug Free Anxiety Treatment
    Infrared Light
    Light Therapy
    Neurofeedback
    Neurotherapy
    Panic Disorder
    Photobiomodulation
    Relaxation
    TBI Treatment
    Therapy

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • Quietmind Foundation
    • Services
    • Clinical Trials >
      • Light Therapy Single Subject Study
      • Intranasal PBM for Long-COVID
  • Quietmind Associates
    • Home Neurofeedback >
      • Research - IRB Review
    • Phototherapeutics & Neurofeedback >
      • Neurofeedback
      • Photobiomodulation (Light Therapy)
    • Equipment
  • Contact
  • BLOG